Eli Lilly | LLY - Кредиторская задолженность





Кредиторская задолженность Изменить Дата
AbbVie USD 3.59B 28.65B 2025-12
Abbott USD 4.68B 439M 2026-03
ALKERMES USD 142.86M 40.5M 2026-06
Amgen USD 19.52B 1.37B 2026-03
AstraZeneca USD 22.89B 388M 2026-06
Baxter International USD 1.03B 52M 2026-06
Biogen USD 403.9M 45.4M 2026-06
Bristol-Myers Squibb USD 4.16B 76M 2026-06
Coherus Biosciences USD 9.91M 14.98M 2025-12
Drreddys Laboratories INR 22.36B 21.91B 2026-03
Eli Lilly USD 5.03B 350M 2026-03
Gilead Sciences USD 645M 70M 2026-03
GlaxoSmithKline GBP 14.34B 7M 2026-06
Glaxosmithkline GBP 14.34B 6.39B 2026-03
J&J USD 9.22B 1.24B 2026-06
Medtronic USD 2.57B 12M 2025-12
Merck USD 3.86B 541M 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novartis USD 4.26B 64M 2026-06
Novartis USD 4.32B 134M 2026-03
Novo Nordisk DKK 14.8B 4.96B 2026-03
Perrigo USD 434.8M 39.7M 2026-03
Pfizer USD 4.51B 734M 2026-03
Phibro Animal Health USD 129.64M 3.65M 2026-03
Prestige Brands USD 22.79M 20.15M 2026-03
Regeneron Pharmaceuticals USD 1.16B 132.2M 2026-06
Roche Holding CHF 5.54B 237M 2026-06
Sanofi EUR 23.6B 888M 2026-06
Sanofi EUR 22.71B 219M 2026-03
United Therapeutics USD 498.3M 491.2M 2026-03
Zoetis USD 507M 20M 2026-03